shen kai pan - Search Results

Year	Number of Results
2010	1
2017	1
2018	1
2019	1
2021	2
2022	3
2023	3
2024	1

1

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.

Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R, Shen K, Pan J, Wang Q, Xue W. Ma Z, et al. Among authors: shen k. Theranostics. 2022 Jun 27;12(11):4965-4979. doi: 10.7150/thno.73152. eCollection 2022. Theranostics. 2022. PMID: 35836810 Free PMC article.

2

SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis.

Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen K, Yue Z, Li W, Xin Z, Zheng Q, Cao Y, Pan J, Dong B, Cheng J, Wang Q, Xue W. Shangguan X, et al. Among authors: shen k. Nat Commun. 2021 Mar 22;12(1):1812. doi: 10.1038/s41467-021-22163-7. Nat Commun. 2021. PMID: 33753739 Free PMC article.

3

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.

Ji Y, Zhang W, Shen K, Su R, Liu X, Ma Z, Liu B, Hu C, Xue Y, Xin Z, Yang Y, Li A, Jiang Z, Jing N, Zhu HH, Dong L, Zhu Y, Dong B, Pan J, Wang Q, Xue W. Ji Y, et al. Among authors: shen k. Nat Commun. 2023 Nov 28;14(1):7794. doi: 10.1038/s41467-023-43676-3. Nat Commun. 2023. PMID: 38016952 Free PMC article.

4

Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition.

Chen L, Liu H, Ji Y, Ma Z, Shen K, Shangguan X, Qian H, Zhao Y, Pan CW, Xue W. Chen L, et al. Among authors: shen k. Exp Cell Res. 2022 Jun 15;415(2):113138. doi: 10.1016/j.yexcr.2022.113138. Epub 2022 Apr 7. Exp Cell Res. 2022. PMID: 35398308

5

The application of "S.I.S" technique improves long-term continence after robotic radical prostatectomy.

Song QX, Li J, Shen K, Peng Z, Qiu X, Zhu H, Gu Y, Xu W, Wang J, Zhu Y, Pan J, Dong B, Xue W. Song QX, et al. Among authors: shen k. Neurourol Urodyn. 2023 Mar;42(3):650-661. doi: 10.1002/nau.25131. Epub 2023 Jan 27. Neurourol Urodyn. 2023. PMID: 36705067

6

HOXD13 suppresses prostate cancer metastasis and BMP4-induced epithelial-mesenchymal transition by inhibiting SMAD1.

Xu F, Shangguan X, Pan J, Yue Z, Shen K, Ji Y, Zhang W, Zhu Y, Sha J, Wang Y, Fan L, Dong B, Wang Q, Xue W. Xu F, et al. Among authors: shen k. Int J Cancer. 2021 Jun 15;148(12):3060-3070. doi: 10.1002/ijc.33494. Epub 2021 Mar 6. Int J Cancer. 2021. PMID: 33521930 Free article.

7

A new breakpoint fusion gene involving KMT2A::EDC4 rearrangement in de novo acute myeloid leukemia.

Hu DY, Wang M, Shen K, Pan JL, Guo YS, Zhang ZB, Zhang FH, Yin J, Chen SN. Hu DY, et al. Among authors: shen k. Int J Lab Hematol. 2023 Aug;45(4):596-598. doi: 10.1111/ijlh.14038. Epub 2023 Feb 21. Int J Lab Hematol. 2023. PMID: 36811287 No abstract available.

8

Tumor exosomes block dendritic cells maturation to decrease the T cell immune response.

Ning Y, Shen K, Wu Q, Sun X, Bai Y, Xie Y, Pan J, Qi C. Ning Y, et al. Among authors: shen k. Immunol Lett. 2018 Jul;199:36-43. doi: 10.1016/j.imlet.2018.05.002. Epub 2018 May 22. Immunol Lett. 2018. PMID: 29800589

9

A novel 4.9 Kb deletion at beta-globin gene is identified by the third-generation sequencing: Case report from Baoan, China.

Chen X, Luo M, Pan L, Huang Y, Yan Z, Shen K, Mai G, Liang H, Li J, Chen Y, Xiong L. Chen X, et al. Among authors: shen k. Clin Chim Acta. 2022 Apr 1;529:10-16. doi: 10.1016/j.cca.2022.01.024. Epub 2022 Feb 9. Clin Chim Acta. 2022. PMID: 35150653

10

Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials.

Tao Z, Li SX, Shen K, Zhao Y, Zeng H, Ma X. Tao Z, et al. Among authors: shen k. Clin Drug Investig. 2019 Jan;39(1):27-43. doi: 10.1007/s40261-018-0719-0. Clin Drug Investig. 2019. PMID: 30370488

BACKGROUND: Neratinib is a novel pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor that has shown promising activity against several types of malignancies, especially HER2-overexpressing breast cancer. ...

BACKGROUND: Neratinib is a novel pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor that has shown promising …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

13 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year